We present the establishment of a natural killer (NK) leukemia cell line, designated KHYG-1, from the blood of a patient with aggressive NK leukemia, which both possessed the same p53 point mutation. 
Introduction
Large granular lymphocyte (LGL) leukemia can be divided into two major groups, T-LGL leukemia and natural killer (NK)-LGL leukemia. 1 T-LGL leukemia presents a mostly indolent and chronic clinical course, a surface CD3 (sCD3)-positive phenotype, and rearrangement of T cell receptor (TCR) genes. [1] [2] [3] In contrast, NK-LGL leukemia exhibits an aggressive clinical course, a lack of sCD3 but a cytoplasmic CD3⑀ (cCD3⑀)
+ phenotype, and a germline configuration of TCR genes. [4] [5] [6] [7] [8] [9] However, variant forms of these two types of LGL leukemia have been reported. 10 An aggressive variant of CD3 + , CD56
+ T-LGL leukemia is now considered to be the leukemic form of NK-like T cell lymphoma.
with an NK cell precursor origin has been reported.
14 Also, the relationship of NK cells to the myeloid lineage has received much attention, and CD7
+ and CD56 + myeloid/NK cell precursor acute leukemia has been proposed as a distinct hematological disease entity. 15 Thus, as diagnostic concepts are refined, the disease spectrum of NK cell leukemia/ lymphoma has recently been expanding. 15 Detailed studies on the clinical and pathological features of such cases contribute to more precise understanding of the emerging clinical spectrum of NK-associated malignancies. Furthermore, the establishment of cell lines from these patients may be of value in studying the cell lineage and the mechanism of NK leukemogenesis.
Since p53 controls the cell cycle checkpoint responsible for maintaining the integrity of the genome, disrupting its function allows tumor cells to avoid the normal restrictions on excessive cell growth. 16 Although p53 mutations occur at a lower frequency in hematological malignancies than in solid tumors, 17 it has been reported that aberrant p53 function appears to permit the identification of prognostically relevant subgroups of patients with acute myeloid leukemia (AML), myelodysplastic syndrome, and aggressive non-Hodgkin's lymphoma. 18, 19 There have also been reports of correlations between p53 mutation and progressive or relapsing disease in juvenile acute lymphocytic leukemia (ALL), 20 adult T cell leukemia, 21 and multiple myeloma. 22 However, there has been no report of p53 mutation in LGL leukemia or of its correlation with disease progression.
We report here a case of aggressive NK cell leukemia having a CD2
+ , CD16 + , CD56 + immunophenotype with a point mutation in exon 7 of the p53 gene. We also have established an NK cell line (KHYG-1) with the same p53 point mutation by culturing peripheral leukemia cells in the presence of interleukin-2 (IL-2). We believe that this is the first human NK leukemia case from which a cell line with the aberrant p53 gene has been established.
Case report
A 45-year old female visited a local physician for progressive general fatigue and a bleeding tendency, and was then referred to our hospital on 25 July 1997. Her mother had died of breast cancer at the age of 68 and her father of stomach cancer at the same age. Her hemoglobin was 9.9 g/dl, hematocrit 28.7%, platelet count (PLT) 1.4 × 10 4 /l, and her white blood cell count (WBC) was 45 500/l with 93% lymphocytes and 7% neutrophils. Review of the peripheral blood smears revealed that the lymphocytes were abnormal with an LGL morphology, as described in the Results. Physical examination revealed apparent hepatosplenomegaly, and lymph node swelling was observed at the bilateral submandibular (1 × 1 cm), right axillary (1 × 2 cm), and bilateral inguinal sites (1 × 2 cm). No mediastinal mass was present in this case. Tests for hepatitis B virus surface antigen and antibody (Ab) to hepatitis C-type virus were negative. Anti-nuclear antibody (ANA) was positive (×160; normal Ͻ×40), but rheumatoid factor was negative. Serologic tests detected no evidence of recent infection with cytomegalovirus, syphilis, human T cell leukemia virus-1, or human immunodeficiency virus-1 or −2. The EB virus serologic examination showed the following titers: EBV capsid antigen (VCA) IgG, ×160; IgM, ×10; EB nuclear antigen (EBNA), ×20. EBV DNA was not detected in the leukemia cells by Southern blot analysis with a terminal repeat probe from the EBV genome (data not shown). Bone marrow aspiration resulted in a dry tap and a subsequent bone marrow biopsy revealed massive infiltration of abnormal lymphocytes. A lymph node biopsy also showed diffuse infiltration by the same abnormal lymphoid cells as seen in the bone marrow. These infiltrating lymphoid cells in the bone marrow and lymph nodes on paraffin sections were shown to be negative for CD20 (L26, DAKO, Glostrup, Denmark) and CD45RO (UCHL-1, DAKO). However, cytoplasmic CD3⑀ was immunohistochemically detected in these cells (data not shown). The patient was then treated with CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisolone). The WBC count decreased in response to therapy; however, the hepatosplenomegaly increased rapidly, and the abnormal lymphocytes increased again in the peripheral blood. Severe thrombocytopenia persisted from the beginning of the clinical course. The patient died on 25 September 1997 of a respiratory hemorrhage. The autopsy revealed the diffuse invasion of leukemia cells into every organ of the body including the skin.
Materials and methods

Cell preparation and culture
Complete medium (CM) was prepared from RPMI 1640 (GIBCO, Paisley, UK), 10% heat-inactivated fetal calf serum (GIBCO), 0.29 mg/ml glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized peripheral blood from the patient by a standard Ficoll-Hypaque density gradient centrifugation. PBMC consisted of 99% leukemia blasts. The cells were washed twice in phosphate-buffered saline (pH 7.4) and incubated in CM containing 100 units of rIL-2 (specific activity: 10 6 U/mg protein; Shionogi Chemical Industries, Osaka, Japan) at 37°C in a 5% CO 2 humidified atmosphere.
Surface phenotype
Surface immunotyping of the primary leukemia or cultured leukemia cells was performed by flow cytometry using a broad panel of monoclonal antibodies (MoAbs) and was confirmed by fluorescence microscopy in some cases. The cells were analyzed on a flow cytometer (Cyto ACE-150 Auto Cell Screener, Japan Spectroscopic Co., Osaka, Japan) for fluorescence intensity using fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated antibodies or unconjugated antibodies followed by fluorescein-conjugated goat antimouse antibodies (Cappel, Aurora, OH, USA). The MoAbs used are listed in Table 1 . Anti-myeloperoxidase (MPO) AM 7, 8, 9 , and 10 antibodies were provided by Dr K Suzuki (National Institute of Health, Tokyo, Japan). 23 Cytoplasmic antigens and TdT were analyzed as described elsewhere. 24 For 
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Cytotoxicity assay
The NK and lymphokine-activated killer (LAK) cell activity of effector leukemia cells were measured by calcein-AM release assay using NK-sensitive K562 cells or NK-resistant Daudi or Raji cells as targets. 26 Briefly, the target cells were labeled with calcein-AM for 30 min at 37°C. Then, the target and effector cells were plated in 96-well plates at the indicated effectorto-target (E/T) ratio and were incubated for 4 h at 37°C in 5% CO 2 humidified air. After incubation, the supernatants were transferred to new wells and fluorescence was measured on a Wallac 1420 ARVO fluoroscan (Wallac, Turku, Finland). The percent cytotoxicity was calculated by the following formula: % lysis = (F experiment − F spontaneous)/(F maximal − F spontaneous) × 100. Assays were performed in triplicate.
Cell proliferation
Leukemic cells from the patient were cultured in a 96-well plate (2 × 10 5 cells/well) in CM containing varying concentrations of rIL-2 or IL-12 (specific activity: 3.57 × 10 6 U/mg protein; Genetics Institute, Cambridge, MA, USA) for 3 days. For proliferation assays, the colorimetric WST-1 assay was used according to the manufacturer's protocol (Takara Shuzo, Otsu, Japan). Briefly, WST-1 (10 l of a 5 mm solution in 20 mm HEPES) was added to all wells, and the plates were incubated for 4 h. The absorbance was measured on an ELISA microplate reader (Iwaki, Osaka, Japan) at a wavelength of 405 nm and a reference wavelength of 650 nm. Also, the cell number after incubation with rIL-2 was calculated by trypan blue dye-exclusion test to check the proliferation of the cells.
Detection of cytokines
The patient's serum and the culture supernatants of leukemia cells incubated in 100 units of rIL-2 were assayed for concentrations of IFN-␥, TNF-␣ and IL-12. The assays were performed by enzyme-linked immunosorbent assay (with a human IFN-␥ EASIA kit (BioSource Europe, Fleurus, Belgium) for IFN-␥, a TNF-␣ measuring kit (Nippon Kotai Institute, Tokyo, Japan) for TNF-␣, and a Quantikine human IL-12 immunoassay kit (R&D Systems, Minneapolis, MN, USA) for IL-12).
Cytogenetic analysis
Karyotype analysis using conventional G-banding techniques was performed on the primary leukemia or cultured leukemia cells.
Southern blot analyses of TCR genes and EB virus genome
High molecular weight DNA was obtained by proteinase K digestion, phenol/chloroform extraction, and precipitation by ethanol. After digestion with the appropriate restriction enzymes, 5 g of DNA was size-fractionated by electrophoresis on a 0.9% agarose gel, denatured, and transferred to nylon membranes (Biodyn B; Pall, Glen Cove, NY, USA) according to standard procedures. The filters were hybridized with specific probes labeled with 32 P by random priming, washed in 0.2% standard saline citrate (SSC)/1% sodium dodecyl sulfate (SDS) for 2 h at 55°C, and autoradiographed at −80°C for 2-4 days.
DNA probes
TCR gene rearrangement analysis was performed on EcoRI, EcoRV, BamHI, or HindIII digests according to the method previously reported. 27 The EBV-specific DNA sequences were detected on EcoRI and BamHI digests with tandem terminal repeated sequences of EBV genomes. 7 
Polymerase chain reaction/single-strand conformation polymorphism (PCR/SSCP)
PCR/SSCP was performed as previously reported. 28 Genomic DNA was amplified by PCR using p53-specific primer pairs. 28 Primers used for PCR were as follows: exon 5f of p53, 5Ј-TCT GTC TCC TTC CTC TTC CT-3Ј; exon 5r of p53, 5Ј-TCT CCA GCC CCA GCT GCT-3Ј; exon 6f of p53, 5Ј-TGA TTC CTC ACT GAT TGC TCT-3Ј; exon 6r of p53, 5Ј-GAG ACC CCA GTT GCA AAC C-3Ј; exon 7f of p53, 5Ј-TCT TGG GCC TGT GTT ATC TC-3Ј; exon 7r of p53; 5Ј-AGG GTG GCA AGT GGC TCC-3Ј; exon 8f of p53, 5Ј-GCT TCT CTT TTC CTA TCC TGA-3Ј; exon 8r of p53, 5Ј-CGC TTC TTG TCC TGC TTG C-3Ј. The number in each designation indicates the region of the exon of the gene subjected to examination by PCR-SSCP. The designation 'f' indicates a sense primer, and 'r' indicates an antisense primer. Forty cycles of PCR amplification were performed as follows: denaturation of 94°C for 1 min, annealing at 60°C for 1 min for exon 5, 6, and 7, and at 55°C for exon 8, extension at 72°C for 1.5 min followed by final extension at 72°C for 7 min.
Seven l of PCR products were diluted with 10 l of buffer consisting of 20 mm EDTA, 96% deionized formamide, and 5 mg/ml Dextran Blue 2000. Heating denature was performed at 95°C for 5 min, after which samples were placed on ice for 5 min. Then, 16 l of this solution was applied to each lane of a 7.5% neutral polyacrylamide gel. Electrophoresis was performed at 15 mA in buffer at a temperature of 18°C (3 h for exon 5, 2.5 h for exons 6, 7 and 8). The gel was stained with 2 g/ml ethidium bromide and visualized under ultraviolet light.
Direct sequencing
DNA fragments amplified by PCR were purified and concentrated with Microcon 100 (Amicon, Beverly, MA, USA), then sequenced with a Taq DyeDeoxy™ Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and an automated sequencer. 29 The primers used for sequencing were the same as those used for PCR-SSCP. To rule out the possibility of errors caused by Taq DNA polymerase, all mutations were confirmed twice.
Results
Establishment of KHYG-1 cell line
The leukemia cells (1 × 10 5 /ml) were cultured in 24-well plates (Corning, Corning, NY, USA) and half the volume of the supernatants was changed twice a week with fresh CM containing 100 units of rIL-2. After 2 weeks, the leukemia cells started to proliferate and they (1-2 × 10 6 ) were transferred to a 25-cm 2 tissue culture flask (Falcon 3013). The cells proliferated continuously as free-floating single cells in suspension. The maximum cell density was 2 × 10 6 cells/ml. The optimal split ratio was 1:4 at 0.5 × 10 6 /ml in CM containing 100 units of rIL-2 every 3-4 days. The established cell line was designated KHYG-1. This cell line has been growing continuously for Ͼ18 months and its doubling time is around 24-48 h. The cells can be cryopreserved in cryopreservation-medium (90% FCS, 10% DMSO), stored in liquid nitrogen, thawed again (with a viability of more than 70%) and successfully reconstituted. The data presented here were obtained from cells that had been in culture for 18 months since establishment.
Morphology of KHYG-1 cells
The leukemia cells observed in the peripheral blood were relatively large, with a high cytoplasm-to-nucleus ratio ( Figure  1a ). Nuclei were irregularly-shaped. Fine azurophilic granules were seen in most of the cells by light microscopy (Figure 1a ), although they were not obvious as observed in regular LGL. After establishment, KHYG-1 cells showed LGL morphology with a large nucleus, coarse chromatin, conspicuous nucleoli, and abundant basophilic cytoplasm with many azurophilic granules (Figure 1b) . These azurophilic granules were negative for MPO by fluorescence microscopy ( Table 1) . − in contrast to the primary leukemia cells (Table 1) . KHYG-1 cells were negative for CD1 (Table 1 ). CD122 (IL-2 receptor ␤-chain) and CD132 (common ␥-chain) were expressed on KHYG-1 cells, but not CD25 (IL-2 receptor ␣-chain). CD158a (EB6) and GL183 (CD158b), two members of the p58 family expressed by discrete subsets of NK cells, were detected in about 50% of the established KHYG-1 cells (Table  1) . KHYG-1 cells were negative for the V␣24 antigen, a human counterpart of mouse NK1.1 expressed on NKT cells. 30 
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Flow cytometry
Cell proliferation
Cytotoxicity
The primary leukemic cells showed a low level of cytotoxicity against K562 cells (13.7% at E/T ratio of 40), which was augmented after incubation with 1000 units of rIL-2 for 24 h (24.7% at E/T ratio of 40). The KHYG-1 cells revealed not only an extremely high level of NK activity against K562 cells, but also LAK activity against NK-resistant Daudi and Raji targets, as shown in Figure 3 .
Cytokine production
Human NK cells produce a variety of cytokines and hematopoietic growth-promoting factors. 31 Although no significant production of IFN-␥, TNF-␣, or IL-12 was detected by ELISA in the serum of the patient, a significant level of IFN-␥ (2.56 ng/ml) and a low level of TNF-␣ (9 pg/ml) was detected in the culture supernatants of KHYG-1 cells in the presence of 100 ng/ml of IL-2. When KHYG-1 cells were stimulated with IL-12 (10 ng/ml) in addition to IL-2 (100 ng/ml), IFN-␥ production increased slightly (4.06 ng/ml). However, TNF-␣ was not detected under those culture conditions (Ͻ5 pg/ml).
Cytogenetics
Chromosome analysis of the peripheral blood leukemia cells was not successful because no metaphase cells were obtained. However, the chromosome analysis of lymph node cells showed a complex karyotype of 47, X, −X, add(6) (q2?), 
DNA analysis
Southern blot analysis revealed that leukemic cells from the peripheral blood were found to retain the germline configuration for the ␤ and ␥ TCR and the immunoglobulin heavy chain genes (data not shown). In addition, established KHYG-1 cells were found to retain the germline configuration for the ␤, ␦ and ␥ TCR genes ( Figure 5 ). EBV DNA was not detected in the KHYG-1 cells by Southern blot analysis using a terminal repeat probe from the EBV genome (not shown).
Detection of point mutation in p53 gene by PCR/SSCP analysis
Most p53 mutations occur in regions of the gene which are highly conserved through evolution, primarily exons 5-8 (codons 126-306). 32 PCR analysis with primers spanning the p53 mutation-prone regions and the subsequent SSCP revealed a mobility shift in exon 7 in both primary leukemia cells and KHYG cells (not shown). When PCR products amplified by exon 7-specific primers from KHYG-1 cells and mutation-negative lung cancer cells (a negative control) were applied to the same lane of the polyacrylamide gel, four bands were clearly observed (data not shown), confirming the mobility shift in p53 exon 7 of KHYG-1 cells. These indicated the presence of mutation(s) in the leukemia cells involving p53 exon 7.
Direct sequences of the p53 gene
Direct sequencing of a PCR-amplified DNA fragment of p53 exon 7 showed the conversion of C to T at the first nucleotide (nucleotide 877) of codon 248 in both the primary leukemia cells and the established KHYG-1 cells. This point mutation results in the substitution of tryptophan for arginine. The wildtype nucleotide band at the site of the base substitution was not detected in either specimen, suggesting the absence of [10] , +X [10] , +X [5] , del(X)(q2?) x4 [10] or i(X)(p10) x4 [10] , +2 [2] , −5 [10] , −5 [10] , add(6)(q2?) [10] , add(6) [8] , ?del(6)(q?) [9] , ?del(6) [2] , −7 [6] , add(7)(q11) x2 [10] , add(7)(q22) [10] , add (7) (10)(p1?) [9] , add(10) [2] , add(11)(q23) [10] , add(11) [8] , +12 [3] , +13 [2] , −13 [3] , −14 [7] , −15 [6] , add(15)(p11) [10] , add(15) [2] , −16 [10] , −16 [8] , +17 [4] , −18 [10] , −18 [10] , +20 [10] , +20 [3] , add (20)(q13) 
Figure 5
Southern blot analysis of the DNA extracted from KHYG-1 cells. No rearranged bands were seen with any probes. C: germline control (human peripheral blood lymphocytes from normal subjects), P: KHYG-1 cells.
wild-type p53 expression. Southern blot analysis was performed to detect alterations in the p53 gene. Southern blots of EcoRI-and BglII-digested DNA hybridized with probes encompassing the entire p53 coding sequence revealed the absence of deletion or rearrangement of the p53 gene (data not shown). The germline p53 mutation of normal tissue (no invasion of leukemia cells) could not be examined in the present case because of the strong invasion of leukemic cells to the whole body. In addition, the examination of other family members for p53 status was not permitted. Therefore, we could not further determine whether this case was Li-Fraumeri syndrome, a hereditary cancer syndrome caused by the inheritance of germline alterations in the p53 gene. 33 
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Discussion
We present here a case of a 45-year-old female patient with aggressive NK cell leukemia with a p53 point mutation and the establishment of an NK leukemia cell line (KHYG-1) with the same mutation. The diagnosis of aggressive NK cell leukemia was based on the aggressive clinical course and in vitro studies of the leukemia cells, including the sCD3
+ immunophenotype, the TCR germline configuration, positive NK cytotoxicity, and IL-2-dependent proliferation.
The characteristics of this case, including the clinical course, resemble the aggressive NK-LGL leukemia/lymphoma reported by Imamura et al. 8 However, the leukemia cells in this case expressed CD8␣␣, a T cell-associated marker, in contrast to Imamura's cases. Also, the KHYG-1 cells established from this patient were positive for CD33, a myeloid antigen, although the fresh leukemia cells did not express it. Therefore, it is necessary to make a careful differential diagnosis with other NK-related leukemias/lymphomas. First, we have to consider the possibility that the origin of the leukemia cells was NK-like T cells, including ␥␦-T cells. However, the leukemia cells of this case were negative for ␣␤-and ␥␦-TCR chains on the cell surface, and they retained the germline configuration for the ␤, ␦ and ␥ TCR genes ( Figure 5 ). The leukemia cells were also negative for the V␣24 antigen which is expressed on NKT cells (Table 1) . 30 Therefore, it seems unlikely that this case was NK-like T cell leukemia/lymphoma of the NKT or ␥␦-T cell types. Second, CD7
+ and CD56
+ myeloid/NK cell precursor acute leukemia is another disease entity to be considered. This type of leukemia has been reported to express a CD34 + , CD33
+ phenotype and to strongly express cytoplasmic MPO. 15 Our case showed a phenotype of CD34
+ and cytoplasmic MPO − (Table  1) . Thus, the present case shows a mature NK phenotype and is considered to be NK cell leukemia. However, the KHYG-1 cells established from the patient were positive for CD33, a myeloid-associated antigen. This suggests that overlapping or borderline cases might exist between NK cell leukemia and myeloid/NK cell precursor acute leukemia. Third, we must also rule out blastic NK cell leukemia. It is characterized by a lymphoblastoid appearance, often with azurophilic granules, EBV negativity and a tendency to involve the skin, lymph nodes, and bone marrow. 34 The leukemia cells of this type of leukemia are usually CD2
+ and TdT
. Since some of these features were found in the present case, it is difficult to make a clear judgment. However, based on the CD2
− immunophenotype of the leukemia cells, our case seems to be a differentiated form rather than a blastic form of NK cell leukemia. Lastly, thymic lymphoblastic lymphoma with a committed NK cell precursor origin can be ruled out due to the CD34 − , CD16 + , TdT − immunophenotype and the absence of a mediastinal mass in the present study.
14 Taken together, we consider the present case to be an aggressive NK cell leukemia, although there are some features shared with other NK-related leukemias such as blastic NK cell leukemia or CD7 + and CD56
+ myeloid/NK cell precursor acute leukemia. Although the KHYG-1 cells retained CD3 + . The induction of CD13 and/or CD33 has been reported in the culture of T-lineage acute lymphoblastoid leukemia cells. 35 Conversely, the antigenic loss of CD16 might occur during the culture of NK cells in the presence of IL-2. However, it was not clear in the present study whether these phenotypic changes were caused by antigenic modulation during culture or by selective growth of the CD16 − , CD33
− population which has an advantage in cultures containing IL-2.
We believe that this is the first human NK leukemia case from which a cell line with a p53 point mutation has been established. The p53 gene, which maps to 17p13, is known as a tumor suppressor gene. 36 Most non-functioning p53 proteins result from missense mutations of one p53 allele coupled with the deletion of the second one. 32 It has been also reported that the mutated p53 may inhibit wild-type p53 and act in a dominant negative fashion even in a heterozygous state. 20, 37 Since the wild-type p53 expression was not detected, p53 function is thought to have been lost or greatly impaired in the present case.
The importance of p53 mutations has been discussed in other hematopoietic cell lines. 38, 39 In a report on the establishment of an NK cell line from a p53 knockout mouse, the authors suggested that genetic intervention of p53 may be a useful strategy for the establishment of cell lines. 40 In the present case, it was easy to establish the cell line by incubating leukemia cells in IL-2 containing medium without any other cytokines or feeder cells. Thus, it is possible that the p53 mutation might have played a role in the establishment of the NK cell line, although it should be further examined whether the p53 mutation alone is a prerequisite for the establishment of the NK cell line.
Ross et al recently reported that apoptosis is induced in normal NK cells or NK cell line cells (NK-92) 41 cultured with both IL-2 and IL-12 in vitro, and that it is mediated by the high level of IFN-␥ and TNF-␣ produced by these NK cells. 42 However, no apoptosis-associated decrease in cell number was observed when KHYG-1 cells were stimulated with both IL-2 (100 ng/ml) and IL-12 (10 ng/ml) for 3 days (data not shown). The most plausible explanation for this observation is that the KHYG-1 cells were able to resist apoptosis because of p53 dysfunction associated with the point mutation.
The important issue is how the aberrant p53 function is involved in the oncogenesis and progression of NK-LGL leukemia. Since the p53-related disruption of the apoptoic pathway may lead to longer survival of lymphocytes, the accumulation of additional genetic lesions is likely to occur. 16 In some human malignancies, the activation of oncogene(s) and inactivation of tumor suppressor gene(s) are considered to play a role in tumorigenesis. 43 In lymphoid leukemia, it has been suggested that the altered p53 gene and the activated K-ras gene cooperate in leukemogenesis. 44 We thus examined alterations in the N-ras, K-ras, retinoblastoma (RB) and interferon responsive factor (IRF) genes. However, no alterations were detected in these genes (data not shown).
Most p53 mutations in leukemia and lymphoma have been reported to occur at CpG dinucleotides, and more than half of the transition mutations are at CpG hot spots (codons 175, 245, 248, 273 and 282), as seen in other solid cancers such as colon and lung cancers. 32 In particular, codons 248, 273 and 282 in the p53 protein contact with the target gene of p53. Therefore, mutations in these codons are now regarded as contact mutations which might acquire stronger carcinogenic ability. [45] [46] [47] In the present case, a point mutation was found at one of the CpG hot spots, codon 248 in exon 7 which is located in the L3-loop of the p53 protein. The establishment of an NK leukemia cell line with a contact mutation may serve as a good model for further study of p53-associated leukemogenesis.
In conclusion, we established an NK leukemia cell line (KHYG-1) from the blood of a patient with aggressive NK leukemia both of which possessed the same p53 point mutation. Several other NK leukemia cell lines have been described. 41, [48] [49] [50] [51] However, NK leukemia cell lines having a p53 point mutation have not been described. This cell line may provide a suitable model to study the mechanism of NK cell leukemogenesis.
Recently, the guideline for the characterization and description of new cell lines has been published. 52 The salient features of KHYG-1 are summarized in Table 2 according to this guideline. 
